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Luteolin Inhibits Proliferation Induced by IGF-1 Pathway Xie*
This effect is mainly exerted through blocking signal transduction in cancer cells (Lin et al., 2008; Dong et al., signaling pathways have been recently shown also to be involved in the metastatic cascade in breast cancer cells (Zhu et al., 2011) . During tumorigenesis, IGF-1 mediated mitogen-activated protein kinase (MAPK) pathway and phosphatidylinositol 3-kinase (PI3K) pathway are important (Sachdev et al., 2001) . For example, Fang et al. (2007) demonstrated that luteolin inhibited prostate cancer through inhibiting IGF-1 mediated MAPK and PI3K pathways. Xia et al. (2007) demonstrated that curcumin exhibited a potent ability to reverse the IGF-1-induced cell growth and apoptosis resistance involving IGF-1 mediated MAPK and PI3K pathway. In addition, it was previously believed that IGF-1 mediated signal transduction pathway is linear, as do most growth factor studies revealed that IGF-1 pathway is also regulated by hormones and intracellular proteins. For example, estrogen positively regulates IGF-1R by promoting IGF-1R and IRS-1 expression, resulting in the downstream activation al. (2001) reported that estrogen stimulates IGF-1R expression, which activates PI3K-Akt pathway, leading to increased mastocarcinoma mitosis. The biological effect of estrogen is primarily mediated through estrogen and auto-regulate the activity of IGF/IGF-1R pathway in breast cancer cells depending on the estrogen receptor status (Sarfstein et al., 2012) . Estrogen binds with estrogen of multiple estrogen responsive genes (for example IGF-1R), leading to the change of related protein levels in between the inhibitory effect of luteolin on the growth systematically studied. To elucidate the target of the our current study investigated relationships among IGF-1 
Materials and Methods
Methyl thiazolyl tetrazolium (MTT) and propidium
Results
At 24 h, cells survial rate in serum-free medium complete medium (containing 10% newborn calf serum). When IGF-1 was added, cell survial rate was enhanced in a dose-dependent manner. After stimulation with IGF-1 at observed in complete medium, respectively. When the cell growth between the cultures for 24 h and 48 h. When cells were treated with different concentrations of IGF-1 for 48 h in serum-free medium, cell survial rate 1). We further observed that the increasing rate of cell proliferation was slowed down when high concentrations conditions for the subsequent experiments.
with IGF-1 alone ( Figure 2A ). When treated for 48 h, compared with IGF-1 treatment, luteolin at (10, 20 or 40 µmol/L) treatment decreased cell viability by (p<0.01) ( Figure 2B ). This data suggests luteolin could inhibit IGF-1-induced cell proliferation effect in a doseand time-dependent manner.
Flow cytometric analysis showed that cell cycle Figure 3A) . In addition, analysis showed that cell apoptosis rate in serum-free control group luteolin and IGF-1 combined treatment increased cell apoptotic rate by 11.28 fold, compared with IGF-1 alone (p<0.01) ( Figure 3B ). This data suggests that luteolin inhibited IGF-1-induced cell cycle progression and resistance of breast cancer cells against apoptosis.
cells treated with IGF-1 increased the amount of p-IGF-1R by 27.38%, respectively (p<0.05), suggesting IGF-1 was able to induce IGF-1R phosphorylation. When cells IGF-1 in serum-free medium, the amount of p-IGF-1R was decreased by 48.83% (p<0.05) 77.57% and 86.20% (p<0.01), compared with IGF-1 treatment (Figure 4 ). This suggests that luteolin could inhibit IGF-1 induced IGF-1R phosphorylation, which acted through IGF-1 mediated signal transduction pathway to exerts its anti-breast cancer effect.
Western blot analysis showed that the amount of p-Akt in IGF-1 group was 1.15 fold that of serum-free control (p<0.05). The amount of p-Erk1/2 was increased, though 88.93% (p<0.01) without an effect on p-Erk1/2 level (p Akt phosphorylation. When PI3K inhibitor LY-294002 was added, the level of p-Akt was declined by 50.10% when compared with treatment with luteolin and IGF-1 combined (p<0.05). Yet when MEK inhibitor PD-98059 5). This suggests that the inhibitory effect of luteolin on IGF-1 induced breast cancer cell proliferation was mainly mediated by PI3K-Akt signal transduction pathway, not by MAPK/Erk1/2 pathway. (Werner et al., 2000; Bustin et al., 2002) . The current experiment showed that when cells enhanced, compared with serum-free control group. our results indicated that IGF-1 was actually one of the results are consistent with previous reports (Kappel et al., 1994; Resnicoff et al., 1995) .
Recently, researchers worldwide started to search for many natural herbs. Recent studies revealed the inhibitory effect of most flavonoids is mainly exerted through blocking IGF-1system in cancer cells. Luteolin, the 3', 4', and has been found to have a wide spectrum of anti-tumor activities. As expected, we documented that luteolin did proliferation and inhibitory effect on apoptosis. These inhibitory effects were associated with a S cell cycle blockage and a sub-G1 apoptotic peak induction. This data suggests that luteolin inhibited IGF-1-induced cell cycle progression and resistance of breast cancer cells studies that showed luteolin exerted its anticancer effects via proliferation inhibition and apoptosis induction in prostate cancer cells. IGF-1 mediated signal transduction pathway is critical in oncogenesis and tumor development (Surmacz primarily mediated through MAPK/Erk1/2 and PI3K-Akt pathways (Dong et al., 2007) . The binding of IGF-1 with the extracellular domain of IGF-1R causes phosphorylation of IGF-1R and downstream substrate, ultimately phosphorylate MAPK and Akt. Thus IGF-1 signal is transmitted to nucleus, initiating gene expression to promote cell proliferation and to inhibit apoptosis. IGF-IR was required for oncogenic transformation and has an established role in breast cancer tumorigenesis (Buck et al., 2010) . Because of its critical importance, the IGF-IR pathway has been intensively studied as a cancer therapeutic target and multiple agents are in clinical development (Yuen et al., 2008; Baserga 2009; Gualberto et al., 2009; Buck et al., 2011) . The current experiment demonstrated that luteolin markedly decreased IGF-1R and Akt phosphorylation without affecting Erk1/2 phosphorylation. The group treated with PI3K inhibitor LY-294002 had lower p-Akt level, compared with the group treated with luteolin. Yet, the group treated with in p-Akt level compared with the groups treated with luteolin. This suggests that the inhibitory effect of luteolin on IGF-1 induced breast cancer cell proliferation was mainly mediated by PI3K-Akt signal transduction pathway, not by MAPK/Erk1/2 pathway.
It was previously believed that IGF-1 mediated signal transduction pathway is linear, as do most growth factor studies revealed that IGF-1 pathway is also regulated by hormones and intracellular proteins. IGF-IR expression level has been associated with ER positivity in both breast in decreased IGF-induced growth and survival (Zhang et expression level, which had an effect on IGF-1-induced lonization mass spectrometry (Wang et al., 2008) . Further studies would be needed to elucidate whether luteolin in decreased IGF-1 signaling pathway.
Taken together, data presented here demonstrate that luteolin exhibited a potent ability to blunt IGFis possibly one of the targets of luteolin. Therefore, we suggest luteolin as a novel drug that may be effective in the treatment of breast cancer.
